Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pivotal Partners China Closes $150 Million Fund to Incubate New Companies

publication date: May 24, 2018

Pivotal bioVenture Partners China, a new early-stage VC funded by Nan Fung Life Sciences, closed its first fund with $150 million. The firm plans to incubate life science companies in China by in-licensing innovative products and technologies, focusing on pharmaceuticals, devices and services. Last year, the US arm of Nan Fung Life Sciences raised $300 million, also for early stage biotech companies though without the China focus. Nan Fung is a Hong Kong conglomerate with interests in real estate, life sciences and finance. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital